Viking Therapeutics (VKTX) Projected to Post Quarterly Earnings on Wednesday

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) is projected to announce its earnings results after the market closes on Wednesday, February 5th. Analysts expect the company to announce earnings of ($0.28) per share for the quarter. Persons that are interested in registering for the company's earnings conference call can do so using this link.

Viking Therapeutics Stock Performance

Shares of Viking Therapeutics stock traded down $0.94 on Friday, reaching $32.75. The company had a trading volume of 3,997,472 shares, compared to its average volume of 3,225,713. The firm's 50 day moving average price is $42.17 and its two-hundred day moving average price is $54.54. Viking Therapeutics has a 52-week low of $22.51 and a 52-week high of $99.41. The firm has a market cap of $3.65 billion, a PE ratio of -35.21 and a beta of 0.95.

Insider Transactions at Viking Therapeutics

In related news, CFO Greg Zante sold 50,309 shares of the company's stock in a transaction on Monday, January 6th. The shares were sold at an average price of $42.75, for a total value of $2,150,709.75. Following the completion of the sale, the chief financial officer now owns 165,259 shares in the company, valued at $7,064,822.25. This represents a 23.34 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Marianna Mancini sold 54,215 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $42.75, for a total transaction of $2,317,691.25. Following the sale, the chief operating officer now owns 374,134 shares of the company's stock, valued at $15,994,228.50. This trade represents a 12.66 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 301,014 shares of company stock worth $12,920,189. Corporate insiders own 4.70% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. William Blair restated an "outperform" rating on shares of Viking Therapeutics in a research report on Wednesday, November 20th. Piper Sandler started coverage on Viking Therapeutics in a report on Monday, December 2nd. They issued an "overweight" rating and a $74.00 target price for the company. B. Riley assumed coverage on Viking Therapeutics in a research report on Friday, November 22nd. They set a "buy" rating and a $109.00 price objective for the company. StockNews.com raised shares of Viking Therapeutics to a "sell" rating in a report on Tuesday, October 15th. Finally, HC Wainwright reiterated a "buy" rating and set a $102.00 price target on shares of Viking Therapeutics in a report on Friday, January 17th. One analyst has rated the stock with a sell rating, eleven have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Viking Therapeutics currently has a consensus rating of "Buy" and an average price target of $106.75.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.